Alirocumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1103 publications
Enlicitide (Lipfendra) - an oral PCSK9 inhibitor for LDL-cholesterol lowering.
Journal: The Medical letter on drugs and therapeutics
Published: August 21, 2026
Response by Fearon et al to Letter Regarding Article, "Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial".
Journal: Circulation
Published: August 03, 2026
Monthly vs. biweekly alirocumab in clinical practice.
Journal: Acta cardiologica
Published: August 03, 2026
JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients.
Journal: Journal of clinical lipidology
Published: July 31, 2026
Drugs for hypertriglyceridemia.
Journal: The Medical letter on drugs and therapeutics
Published: July 14, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Journal: Research square
Published: July 03, 2026
A Comprehensive Review of PCSK9 Inhibitor Therapy.
Journal: Journal of cardiovascular pharmacology
Published: July 02, 2026
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.
Journal: American journal of therapeutics
Published: June 24, 2026
Listening to patients' questions: what the HEAR Project reveals about alirocumab use in routine care.
Journal: European journal of cardiovascular nursing
Published: June 14, 2026
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Last Updated: 09/26/2026